Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06980077 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ivonescimab for the Treatment of Thymic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 1 of 5 sites
  2. Eligibility criteria expanded, about 65 words
    • Site details revised at 2 of 5 sites
  3. Re-verified, no change to tracked fieldsv5
  4. Study sites: 1 to 5v4
  5. Site contact updatedv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 17, 2025 to Jul 15, 2025
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Trial Details
NCT Number NCT06980077
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Summit Therapeutics
Conditions
(from sponsor)		 Thymus Carcinoma
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov